Journal of the American College of Surgeons
Volume 201, Issue 3 , Pages 418-425, September 2005

Melanoma Inhibits Macrophage Activation by Suppressing Toll-like Receptor 4 Signaling

Abstract presented at the American College of Surgeons 89th Annual Clinical Congress, Surgical Forum, Chicago, IL, October 2003.

  • Jason H. Clarke, MD

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • John Y. Cha, MD

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Mark D. Walsh, MD

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Fabia Gamboni-Robertson, PhD

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Anirban Banerjee, PhD

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Leonid L. Reznikov, MD, PhD

      Affiliations

    • Department of Medicine, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Charles A. Dinarello, MD

      Affiliations

    • Department of Medicine, University of Colorado Health Sciences Center, Denver, CO
  • ,
  • Alden H. Harken, MD (FACS)

      Affiliations

    • Department of Surgery, University of California San Francisco - East Bay, San Francisco, CA.
  • ,
  • Martin D. McCarter, MD (FACS)

      Affiliations

    • Department of Surgery, University of Colorado Health Sciences Center, Denver, CO
    • Corresponding Author InformationCorrespondence address: Martin D McCarter, MD, Department of Surgery, University of Colorado Health Sciences Center, 4200 East Ninth Ave, C-311, Denver, CO 80262.

Received 5 October 2004; received in revised form 11 April 2005; accepted 29 April 2005.

Background

Activated macrophages defend against tumors by secreting cytokines to recruit secondary immune cells, presenting antigen to T cells, and by direct tumor cytotoxicity. Peritoneal macrophages harvested from melanoma-bearing mice are less cytotoxic to melanoma cells, and produce less superoxide, nitric oxide, and tumor necrosis factor-α (TNF-α) than those from nontumor-bearing mice. Similar impairment of macrophage activation occurs in vitro using media harvested from cultured melanoma cells. Stimulation of Toll-like receptor 4 (TLR-4) activates macrophages and results in the release of TNF-α. We hypothesized that melanoma inhibits macrophage activation by suppressing TLR-4 signaling.

Study design

Melanoma conditioned media (MCM) was generated from B16 melanoma cells. Peritoneal macrophages from TLR-4 competent or TLR-4 incompetent mice were exposed to control or MCM for 24hours; then stimulated with lipopolysaccharide. TNF-α secretion, TNF-α mRNA production, nuclear factor-κB (NF-κB) activation, and TLR-4 surface expression were measured.

Results

Peritoneal macrophages exposed to MCM produced considerably less TNF-α in response to stimulus than controls (691 pg/mL versus 2,066 pg/mL, p < 0.001). TNF-α production by TLR-4 incompetent macrophages was not affected by MCM (454 pg/mL versus 480 pg/mL). Stimulated TNF-α mRNA and activated NF-κB were decreased in MCM treated C57BL/6 macrophages (by 38% and 33%, respectively). TLR-4 surface expression, however, was not decreased by exposure to MCM.

Conclusions

Melanoma inhibits macrophage activation by suppressing TLR-4 signaling downstream of the TLR-4 receptor.

Abbreviations and Acronyms:  αMSH, alpha-melanocyte stimulating hormone , DMEM, Dulbecco’s modified Eagle’s medium , FBS, fetal bovine serum , LPS, lipopolysaccharide , MCM, melanoma conditioned media , NF-κB, nuclear factor-κB , NO, nitric oxide , RNA, Ribonucleic acid , TLR, Toll-like receptor , TNF-α, tumor necrosis factor-α

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Competing Interests Declared: None.This work supported in part by a 5K12CA86913 Clinical Oncology Research Cancer Development program award, National Institutes of Health Grants GM-49222, GM-08315, AI-15614, and HL-68743, and Colorado Cancer Center Grant CA-046934.

PII: S1072-7515(05)00605-8

doi:10.1016/j.jamcollsurg.2005.04.035

Journal of the American College of Surgeons
Volume 201, Issue 3 , Pages 418-425, September 2005